DLLLGTLNI is a linear peptidic epitope (epitope ID 110206) studied as part of Protein E7 (UniProt:P04020) from Human papillomavirus 11 (HPV 11), which belongs to Alphapapillomavirus 10. This epitope has been studied for immune reactivity and has been tested in T cell assays.
YMLDLQPET is a linear peptide epitope corresponding to residues 11 through 19 of the E7 oncoprotein from Human papillomavirus type 16 (HPV-16, UniProt: P03129) and HPV-18 (UniProt: P06788). Classified under epitope ID 75074, this sequence is associated with the Alphapapillomavirus 9 and Alphapapillomavirus 7 species groups, respectively.
This HLA-A*02:01-restricted epitope has been extensively characterized for its immunological relevance, including its capacity to be recognized by both CD8⁺ T cells and B cells. It has been tested in T cell functional assays, B cell reactivity assays, and MHC class I ligand binding studies, highlighting its value in HPV-specific immune monitoring and vaccine development.
The E7 protein itself plays a central role in HPV-driven oncogenesis. It interferes with host immune responses, making E7-derived epitopes such as YMLDLQPET particularly important in the context of cancer immunotherapy research.
This peptide is frequently used in experimental settings involving antigen presentation, cytotoxic T lymphocyte responses, and the evaluation of HPV-targeted immunotherapeutic strategies.
YMLDLQPETT is a linear epitope spanning amino acids 11 to 20 of the E7 oncoproteins from Human papillomavirus type 16 (HPV-16, UniProt: P03129) and type 18 (HPV-18, UniProt: P06788), both high-risk, oncogenic HPV types. The peptide is listed under epitope ID 75075.
The peptide is presented by HLA-A*02:01, a common MHC class I allele, and has been extensively validated for its immunogenic potential. It has been extensively tested in T cell assays, B cell assays, and MHC binding assays, highlighting its broad application in HPV-specific immunity studies and vaccine research.
The E7 protein plays a pivotal role in HPV-mediated carcinogenesis by disrupting immune recognition pathways. Peptides derived from this region, such as YMLDLQPETT, are of particular interest for T cell-based immunotherapies.
This peptide is available from stockand ready for immediate shipping to support your research needs.
MLDLQPETT is a linear peptidic epitope (epitope ID41919) studied as part of Protein E7 (UniProt:P03129) from Human papillomavirus type 16 and Protein E7 (UniProt:P06788) from Human papillomavirus type 18. This epitope has been tested in T cell assays, B cell assays and MHC ligand assays.
RAHYNIVTF is a well-characterized linear epitope derived from residues 49 to 57 of the E7 oncoprotein of Human papillomavirus type 16 (HPV-16, UniProt: P03129), as well as the homologous sequence from HPV-18 (UniProt: P06788). This H-2 Db-restricted peptide is catalogued under epitope ID 53112.
Widely recognized for its robust immunogenicity in murine models, RAHYNIVTF has been investigated in over a hundred scientific publications. It has been tested in T cell assays, especially, but also in B cell assay and MHC ligand binding assays. Its widespread use in immunological studies makes it one of the most thoroughly validated HPV E7 epitopes available.
This peptide has been evaluated across a diverse range of functional T cell assays, including:
- Cytotoxicity and T cell activation
- TNF-α, IL-2, IL-4, IL-10, TGF-β, and granzyme B release
- Proliferation and degranulation assays
- Pathogen and tumor burden post-challenge
- Survival outcomes in viral or tumor models
- Adoptive transfer and protection assays
Due to its proven utility in preclinical tumor models and viral immunity research, RAHYNIVTF serves as a key tool for studying antigen-specific CD8⁺ T cell responses in the context of HPV-related cancer immunotherapy and vaccine development.
This peptide is in stock and available for immediate delivery.
GIVCPICSQKis a linear peptidic epitope (epitope ID 20471) studied as part of Protein E7 (UniProt:P03129) fromHuman papillomavirus type 16(HPV 16) and Protein E7 (UniProt:P06788) fromHuman papillomavirus type 18(HPV 18). This epitope has been studied for immune reactivity and has been tested in T cell assays and MHC ligand assays.
Pool of 124 peptides derived from a peptide scan (15mers with 11 aa overlap) through Protein L1 (Swiss-Prot ID: Q9WLQ6) of Human papillomavirus - type 16
One unit allows the stimulation of 2,5 x 108 cells.
Pool of 116 peptides derived from a peptide scan (15mers with 11 aa overlap) through Protein L2 (Swiss-Prot ID: P03107) of Human papillomavirus - type 16.
One unit allows the stimulation of 2,5 x 108 cells.
Pool of 89 peptides derived from a peptide scan (15mers with 11 aa overlap) through Regulatory protein E2 (UniProt ID: P03120) of Human papillomavirus type 16.
One unit allows the stimulation of 2,5 x 108 cells.
Pool of 18 peptides derived from a peptide scan (15mers with 11 aa overlap) through Probable protein E5 (UniProt ID: P06927) of Human papillomavirus type 16.
One unit allows the stimulation of 2,5 x 108 cells.
Pool of 37 peptides derived from a peptide scan (15mers with 11 aa overlap) through Protein E6 (Swiss-Prot ID: P03126) of Human papillomavirus type 16.
One unit allows the stimulation of 2,5 x 108 cells.
Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap) through Protein E7 (Swiss-Prot ID: P03129) of Human papillomavirus.
One unit allows the stimulation of 2,5 x 108 cells.
Pool of 140 peptides derived from a peptide scan (15mers with 11 aa overlap) through Protein L1 (Swiss-Prot ID: P06794) of Human papillomavirus - type 18.
One unit allows the stimulation of 2,5 x 108 cells.
Pool of 113 peptides derived from a peptide scan (15mers with 11 aa overlap) through Protein L2 (Swiss-Prot ID: P06793) of Human papillomavirus.
One unit allows the stimulation of 2,5 x 108cells.
Pool of 89 peptides derived from a peptide scan (15mers with 11 aa overlap) through Regulatory protein E2 (UniProt ID: P06790) of Human papillomavirus type 18.
One unit allows the stimulation of 2,5 x 108 cells.
Pool of 16 peptides derived from a peptide scan (15mers with 11 aa overlap) through Probable protein E5 (UniProt ID: P06792) of Human papillomavirus type 18.
One unit allows the stimulation of 2,5 x 108 cells.
Pool of 37 peptides derived from a peptide scan (15mers with 11 aa overlap) through Protein E6 (UniProt ID: P06463) of Human papillomavirus type 18.
One unit allows the stimulation of 2,5 x 108 cells.
Pool of 24 peptides derived from a peptide scan (15mers with 11 aa overlap) throughProtein E7(UniProt ID: P06788) of Human papillomavirus type 18.
One unit allows the stimulation of 2,5 x 108cells.
Regulärer Preis:
261,90 €*
Diese Website verwendet Cookies, um eine bestmögliche Erfahrung bieten zu können. Mehr Informationen ...
